This clinical trial is focused on studying the effects of a medication called deucravacitinib on individuals with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body. The medication being tested, deucravacitinib, is taken orally in the form of a film-coated tablet. The study also includes a comparison with a placebo to evaluate the effectiveness and safety of deucravacitinib.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.